Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
AbstractHepatocellular carcinoma (HCC) is the most common form of liver cancer and is the third leading cause of cancer-related deaths worldwide. Treatment options for HCC are very limited, as it is often diagnosed at a late stage. Recent studies have demonstrated that microRNAs (miRNAs), a class of non-coding RNAs, are aberrantly expressed in HCC. Some of these were shown to be functionally involved in carcinogenesis and tumor progression, suggesting that miRNAs can serve as novel molecular targets for HCC therapy. Several promising studies have recently demonstrated the therapeutic potential of miRNAs in animal models and in reducing the viral load in hepatitis C patients. In this review, these advances and strategies for modulating miRNAs for in vivo therapeutic delivery and replacement therapy are discussed. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Aravalli, R.N. Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics 2013, 3, 170-191.
Aravalli RN. Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics. 2013; 3(1):170-191.Chicago/Turabian Style
Aravalli, Rajagopal N. 2013. "Development of MicroRNA Therapeutics for Hepatocellular Carcinoma." Diagnostics 3, no. 1: 170-191.